EUVIMEDEUVIMED entdecken
Crossref

Gene Expression Profiling in Acute Myeloid Leukemia Patient Subgroups With High and Low Sensitivity Toward SYK Inhibitors

Marte Karen Brattås iD, Franziska Görtler, Silje Johansen, Kristin Paulsen Rye, Kimberley Joanne Hatfield, Håkon Reikvam

Hematological Oncology · 2025

DOI: 10.1002/hon.70058 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hematological Oncology, 2025. Verfasst von Marte Karen Brattås und 5 weiteren Autor:innen. Beteiligte Einrichtung: K.G. Jebsen Center for Myeloid Malignancies, Institute of Clinical Science, University of Bergen, Bergen, Norway. Hauptthemen laut MEDLINE: Syk Kinase, Leukemia, Myeloid, Acute, Gene Expression Profiling, Protein Kinase Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: Helse Vest, Universitetet i Bergen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acute myeloid leukemia (AML) is a heterogeneous malignancy characterized by the uncontrolled proliferation of myeloid cells, and despite recent treatment advances, patient outcomes remain suboptimal. The cytoplasmic spleen tyrosine kinase (SYK) has emerged as a promising therapeutic target in AML due to its role in promoting leukemic cell survival, proliferation, and chemoresistance. This study investigates in vitro antiproliferative effects of SYK inhibitors on leukemia cells by analyzing 48 primary AML samples treated with five SYK inhibitors: fostamatinib, entospletinib, cerdulatinib, TAK‐659, and RO9021. Our findings revealed significant heterogeneity among patients, leading to the identification of two distinct patient sample groups that were identified as having either high or low sensitivity toward SYK inhibitors. Furthermore, gene expression profiling through RNA sequencing of AML patient samples uncovered 97 significantly differentially expressed genes (DEGs) between the two patient groups with high or low in vitro sensitivity toward SYK inhibitors. Pathway enrichment analyses revealed that the high‐sensitivity group was enriched in biological processes related to positive gene regulation and significant pathways included cell adhesion molecules and proteoglycans. In contrast, the low‐sensitivity group showed enrichment in pathways related to PI3K‐Akt signaling and JAK‐STAT signaling. Gene set enrichment analysis further highlighted that high‐sensitivity patient samples were upregulated in pathways associated with oxidative phosphorylation and MYC targets, whereas low‐sensitivity patient samples showed enrichment in TGF beta signaling and IL6 JAK STAT3 signaling. These results identify gene expression profile signatures that may predict sensitivity to SYK inhibition and underscore the potential for personalized therapeutic strategies in AML.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Syk KinaseLeukemia, Myeloid, AcuteGene Expression ProfilingProtein Kinase InhibitorsGene Expression Regulation, LeukemicDrug Resistance, NeoplasmHumansMaleFemaleMiddle AgedAdultAged

Stichwörter der Autor:innen

acute myeloid leukemiagene expression profilingspleen tyrosine kinase

Substanzen

Syk KinaseSYK protein, humanProtein Kinase Inhibitors

Autor:innen und Institutionen

  • K.G. Jebsen Center for Myeloid Malignancies, Institute of Clinical Science, University of Bergen, Bergen, Norway.
  • Section for Hematology, Department of Medicine, Haukeland University Hospital, Bergen, Norway.
  • Department of Oncology and Medical Physics, Haukeland University Hospital, Bergen, Norway.
  • Section for Hematology, Department of Medicine, Haraldsplass Deaconess Hospital, Bergen, Norway.
  • Department of Immunology and Transfusion Medicine, Haukeland University Hospital, Bergen, Norway.

ORCID-Profile: Marte Karen Brattås

Förderung

  • Helse Vest
  • Universitetet i Bergen

Zitieren

APA

Brattås, M. K., Görtler, F., Johansen, S., Rye, K. P., Hatfield, K. J., & Reikvam, H. (2025). Gene Expression Profiling in Acute Myeloid Leukemia Patient Subgroups With High and Low Sensitivity Toward SYK Inhibitors. Hematological Oncology. https://doi.org/10.1002/hon.70058

Vancouver

Brattås MK, Görtler F, Johansen S, Rye KP, Hatfield KJ, Reikvam H. Gene Expression Profiling in Acute Myeloid Leukemia Patient Subgroups With High and Low Sensitivity Toward SYK Inhibitors. Hematological Oncology. 2025. doi:10.1002/hon.70058

BibTeX
@article{Bratts2025,
  author = {Brattås, Marte Karen and Görtler, Franziska and Johansen, Silje and Rye, Kristin Paulsen and Hatfield, Kimberley Joanne and Reikvam, Håkon},
  title = {Gene Expression Profiling in Acute Myeloid Leukemia Patient Subgroups With High and Low Sensitivity Toward SYK Inhibitors},
  journal = {Hematological Oncology},
  year = {2025},
  doi = {10.1002/hon.70058}
}
Kostenlos starten →